Orion Q4 and Full Year Report 2013

Orion Group Financial Statement Release for 2013 and Outlook for 2014.

• Orion’s net sales in 2013 totalled EUR 1,007 million (EUR 980 million in 2012), up by 3% on the previous year.

• Operating profit was EUR 268 (278) million.

• Profit before taxes was EUR 264 (277) million.

• Equity ratio was 54% (61%).

• ROCE before taxes was 39% (46%).

• ROE after taxes was 40% (41%).

• Basic earnings per share were EUR 1.46 (1.47).

• Cash flow per share before financial items was EUR 1.02 (1.23).

• Board’s proposal for dividend per share is EUR 1.25 (1.30).

• Orion has signed a licensing agreement with Janssen Pharmaceuticals for development and commercialisation of ORM-12741.

Outlook for 2014

• Net sales will be at similar level to 2013 (net sales in 2013 were EUR 1,007 million).

• Operating profit will be slightly lower than in 2013 (operating profit in 2013 was EUR 268 million).

• The Group’s capital expenditure will be about EUR 60 million excluding substantial corporate or product acquisitions (the Group’s capital expenditure in 2013 was EUR 78 million).

For more information, click the link below
Orion Q4-2013

Tweet